ISCHEMIA Trial: Was It Worth the Wait?

Rasha Al-Lamee, MBBS, MA, PhD; Alice K. Jacobs, MD


Circulation. 2020;142(5):517-519. 

In This Article

What do we Still Need to Know?

It will be very important to obtain longer-term follow-up data, not only to watch the trajectory of the outcome curves but to better understand the relationship between early and late hazards, particularly for MI. We will need to assess comparative outcomes in patients with and without complete revascularization in the invasive arm and comparative outcomes in patients who did and did not adhere to optimal GDMT.